Tags : Modag

PharmaShots Weekly Snapshots (October 25 – 29, 2021)

Tuba Khan October 29, 2021

ADC Reports EMA’s Validation of MAA for Zynlonta to Treat R/R Diffuse Large B-Cell Lymphoma Published: Oct 29, 2021 | Tags: ADC, EMA, MAA, Zynlonta, R/R Diffuse Large B-Cell Lymphoma […]readmore

Pharma

Teva Signs an Exclusive WW License Agreement with Modag to

Tuba Khan October 27, 2021

Shots: Teva to get an exclusive license globally to develop, manufacture & commercialize anle138b &sery433. Additionally, both companies will jointly develop the products for MSA & PD based on early-stage […]readmore

Tags : Modag

PharmaShots Weekly Snapshots (October 25 – 29, 2021)

Teva Signs an Exclusive WW License Agreement with Modag to

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Modag

PharmaShots Weekly Snapshots (October 25 – 29, 2021)

Teva Signs an Exclusive WW License Agreement with Modag to

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company